IGC

IGC Pharma, Inc.

Investor Moves

InvestorPortfolio ValuePortfolio ChangePosition ChangeAvg Buy PriceCurrent Price
Jim SimonsRenaissance Technologies
$127k484k shares
TrimQ1 2026
$132k
$0.263
$0.2897
Ken GriffinCitadel Advisors
$-78.1K
ExitQ1 2026
$78k
--
$0.2897
Ken FisherFisher Asset Management
$11k43.4k shares
TrimQ1 2026
$798
$0.263
$0.2897
Jim SimonsRenaissance Technologies
$259k919.6k shares
TrimQ4 2025
$249k
$0.2814
$0.2897
Ken GriffinCitadel Advisors
$78k277.6k shares
TrimQ4 2025
$184k
$0.2814
$0.2897
Ken FisherFisher Asset Management
$12k43.4k shares
TrimQ4 2025
$5.9k
$0.2814
$0.2897

News

accessnewswire.comAscendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalystsaccessnewswire.comJun 9accessnewswire.comIGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysisaccessnewswire.comJun 2accessnewswire.comIGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollmentaccessnewswire.comMay 19accessnewswire.comIGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conferenceaccessnewswire.comMay 15accessnewswire.comIGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phaseaccessnewswire.comApr 28